Table 2.
Cox regression analysis for clinical outcomes in EOC patients.
| Characteristics | HR for overall survival (95% CI) | HR for progression-free interval (95% CI) | HR for disease-specific survival (95% CI) | |||
|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | |
| Age (>60 vs ≤60 yr) | 1.355* | 1.316 | 1.255 | NA | 1.255 | NA |
| FIGO stage (I & II vs III & IV) | 2.115 | 2.602 | 1.573 | 1.558 | 2.276 | 2.474 |
| Primary therapy outcome (PD & D vs PR & CR) | 0.301*** | 0.317*** | 0.457*** | 0.507*** | 0.294*** | 0.33*** |
| MMP17 (high vs low) | 1.639*** | 1.488*** | 1.39** | 1.347** | 1.693*** | 1.548** |
| Race (White vs Black or African American and Asian) | 0.637 | 0.61 | 0.843 | NA | 0.592* | 0.601 |
CI = confidence interval, EOC = epithelial ovarian cancer, FIGO = Federation International of Gynecology and Obstetrics, HR = hazard ratio, MMP17 = matrix metalloproteinase 17.
*
P < .05.
**
P < .01.
***
P < .001.